Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 151 - 175 of 199 in total
TAK-733 has been used in trials studying the treatment of Advanced Metastatic Melanoma, Advanced Nonhematologic Malignancies, and Advanced Non-hematologic Malignancies.
Investigational
CI-1040 has been used in trials studying the treatment of Lung Cancer, Breast Cancer, Breast Neoplasms, Pancreatic Cancer, and Colorectal Cancer, among others.
Investigational
Withdrawn from the Canadian, US, and UK markets in 1963 due to nephropathy.
Withdrawn
A product from the iodination of MONOIODOTYROSINE. In the biosynthesis of thyroid hormones, diiodotyrosine residues are coupled with other monoiodotyrosine or diiodotyrosine residues to form T4 or T3 thyroid hormones (THYROXINE and TRIIODOTHYRONINE). [PubChem]
Experimental
GDC-0623 has been used in trials studying the treatment of Solid Cancers.
Investigational
Investigational
Iofolastat I-123 is under investigation in clinical trial NCT00992745 (A Phase I Pilot Study Comparing 123I MIP 1072 Versus 111In Capromab Pendetide in Subjects With Metastatic Prostate Cancer).
Investigational
Experimental
Experimental
Investigational
Iodamide is a contrast medium molecule that is no longer marketed in the United States.
Withdrawn
Experimental
Iopentol is used as a contrast medium.
Experimental
CF 101 (known generically as IB-MECA) is an anti-inflammatory drug for rheumatoid arthritis patients. Its novel mechanism of action relies on antagonism of adenoside A3 receptors. CF101 is supplied as an oral drug and has an excellent safety profile. It is also being considered for the treatment of other autoimmune-inflammatory...
Investigational
Displaying drugs 151 - 175 of 199 in total